RxDoctor Payments Data

Victor Chiu, MD

Hematology & Oncology · Mesa, AZNPI 1144548652

Payments from drug & device makers

$515,072in general payments, 2019–2025

Across 265 payments — averaging $1943.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$459K
  • AstraZeneca$37K
  • Sanofi US Services Inc.$14K
  • Janssen Research & Development, LLC$794
  • Novartis$509
  • Pfizer$476
  • plus $4K from 40 others
$509in research payments, 2019–2025

Across 2 payments — averaging $254.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$509

What the payments were for

  • Consulting fees$3,79041%
  • Food & beverage$5,50759%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$515,072 in reported general payments places this provider in the 75th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$2,947,315
Medicare patients
547
Services billed
159,735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide18$270,862
VerzenioAbemaciclib12$200,140
BrukinsaZanubrutinib12$181,123
SprycelDasatinib11$115,836
EliquisApixaban76$79,965
XareltoRivaroxaban28$34,873
Abiraterone Acetate30$25,973
Anastrozole208$4,595
Exemestane30$4,225
Ondansetron OdtOndansetron82$1,324
Letrozole25$925
Hydroxyurea40$851
Dexamethasone31$653
Levothyroxine Sodium41$578
Acyclovir21$430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Beigene USA, Inc.Brukinsa$23$181,12312 claims
E.r. Squibb & Sons, L.L.C.Sprycel$106$115,83611 claims
PfizerEliquis$476$79,96576 claims
Johnson & JohnsonXarelto$77$34,87328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 261 hematology & oncology providers in Arizona.

Other hematology & oncology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →